{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "IRON", "name": "Disc Medicine, Inc.", "url": "https://frontierpicks.com/dossiers/IRON/", "json_url": "https://frontierpicks.com/dossiers/IRON.json", "status": "WATCHLIST", "current_conviction": "MEDIUM", "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19 October 2026, answering the FDA's February rejection. ASH pipeline data from 12 December 2026 and the NDA resubmission guided for the end of 2026 decide it.", "invalidation_trigger": "A daily close below $78.47, the 2026-11-05 close on the day of the third-quarter report and the at-the-market filing, which would erase the post-report gains; or no bitopertin NDA resubmission announced by 2026-12-31.", "catalyst_date": "2026-12-12", "portfolio": null, "pick": null, "themes": [ "rare-disease-gene-therapy", "binary-catalyst-biotech" ], "tags": [], "sources": [], "caveats": [ { "claim": "Disc Medicine has no approved product; its revenue and valuation depend on FDA approval of bitopertin, which the company expects by mid-2027.", "source": "Third-quarter 2026 results release, 2026-11-05", "as_of": "2026-11-05" }, { "claim": "An at-the-market sales agreement with TD Cowen allows the company to sell up to $189.93 million of common stock over time.", "source": "Sales agreement with TD Cowen, filed with the SEC 2026-11-05", "as_of": "2026-11-05" }, { "claim": "News about Ironveld plc, a UK-listed miner, sometimes appears under the IRON ticker and is unrelated to Disc Medicine.", "source": "Ironveld plc announcement on Layer 21 discovery, 2026-10-30", "as_of": "2026-10-30" } ], "source_links": [ { "title": "Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)", "url": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-success-all-primary-and-secondary", "date": null }, { "title": "Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2026/11/05/3396436/0/en/disc-medicine-reports-third-quarter-2026-financial-results-and-provides-business-update.html", "date": "2026-11-05" }, { "title": "Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep", "url": "https://www.biospace.com/drug-development/discs-rebuffed-rare-disease-drug-sets-up-fda-re-do-after-clean-phase-3-sweep", "date": "2026-10-19" }, { "title": "Disc Medicine at Guggenheim conference: cash-rich push into launch phase", "url": "https://au.investing.com/news/stock-market-news/disc-medicine-at-guggenheim-conference-cashrich-push-into-launch-phase-93CH-4756261", "date": "2026-11-10" }, { "title": "hcplive.com", "url": "https://www.hcplive.com/view/fda-issues-complete-response-letter-bitopertin-erythropoietic-protoporphyria", "date": "2026-02-13" }, { "title": "pharmexec.com", "url": "https://www.pharmexec.com/view/fda-crl-disc-medicine-eythropoietic-protoporphyria-treatment-bitopertin", "date": "2026-02-16" }, { "title": "Explore the Premier Event in Classical and Malignant Hematology", "url": "https://www.hematology.org/meetings/annual-meeting", "date": null } ], "evidence": [ { "claim": "Phase 3 APOLLO (183 patients) met all primary and secondary endpoints: PPIX down 41.4% against placebo (p<0.0001), 12.2 more hours a month of time in light without pain (p=0.0010).", "source": "Disc Medicine press release, 2026-10-19", "as_of": "2026-10-19" }, { "claim": "The FDA's complete response letter for bitopertin in EPP said the PPIX surrogate was not shown to predict clinical benefit and asked for data from another trial.", "source": "HCPLive and PharmExec coverage of the CRL, 2026-02-13 and 2026-02-16", "as_of": "2026-02-13" }, { "claim": "Cash, equivalents and marketable securities were $682.8 million at 2026-09-30; the company guides runway into 2030 including the October offering proceeds.", "source": "Third-quarter 2026 results release, 2026-11-05", "as_of": "2026-11-05" }, { "claim": "Upsized public offering of 6,000,000 shares priced at $75.00, for $450 million gross proceeds.", "source": "Disc Medicine offering pricing release, 2026-10-21", "as_of": "2026-10-21" }, { "claim": "At-the-market sales agreement with TD Cowen for up to $189.93 million of common stock.", "source": "Disc Medicine sales agreement filing, 2026-11-05", "as_of": "2026-11-05" }, { "claim": "CEO John Quisel said bitopertin could launch in 12 to 16 months and cited about $1.1 billion of pro forma cash and about $300,000 a year EPP pricing.", "source": "Guggenheim Healthcare Innovation Conference, 2026-11-09 (Investing.com)", "as_of": "2026-11-09" }, { "claim": "Guggenheim initiated coverage at Buy with a $132 target on 2026-11-09; HC Wainwright raised its target to $127 on 2026-11-06.", "source": "Benzinga analyst reports, 2026-11-06 and 2026-11-09", "as_of": "2026-11-09" }, { "claim": "Chief Medical Officer William Jacob Savage sold 16,035 shares at $85.09 on 2026-11-10 under a Rule 10b5-1 plan.", "source": "SEC Form 4 filed 2026-11-12", "as_of": "2026-11-12" } ], "view_changes": [], "frame": { "as_of": "2026-11-15", "business": "Disc Medicine develops drugs for blood disorders: bitopertin for erythropoietic protoporphyria (EPP), a rare sunlight-sensitivity disease, plus selcodebart and DISC-3405. It has no approved product and no product revenue, lost $60 million in the quarter to 2026-09-30, and funds itself by selling shares.", "change": { "now": "On 2026-10-19 Disc Medicine reported that bitopertin met all primary and secondary endpoints of the Phase 3 APOLLO trial, the further trial data the FDA's 2026-02-13 rejection letter asked for.", "next": "The company raised $450 million gross at $75.00 a share on 2026-10-21, filed a TD Cowen at-the-market program for up to $189.93 million on 2026-11-05, guides cash into 2030 and plans a 24-person EPP sales force.", "linked": "Clinuvel (CLVLY), maker of Scenesse, the approved EPP implant, would face an oral rival; DISC-3405 competes in polycythemia vera with rusfertide from Protagonist Therapeutics (PTGX) and Takeda (TAK)." }, "priced_in": "At the 2026-11-13 close (filed inputs to 2026-11-05) the shares trade at 6.0 times book and a −5.2% free-cash-flow yield, for an enterprise value of $3,020 million; EV/sales is not available and P/E not meaningful. That holds only if bitopertin is approved and its sales replace the $190 million operating cash burn of the four quarters to 2026-09-30.", "links": { "customers": [], "suppliers": [], "competitors": [ { "ticker": "PTGX", "url": "https://frontierpicks.com/dossiers/PTGX/" }, { "ticker": "TAK", "url": null } ] } }, "filed_numbers": { "as_of": "2026-11-13", "sector": "Healthcare", "financials": { "status": "ok", "reason": null, "close_date": "2026-11-13", "latest_quarter": "2026-09-30", "figures": { "revenue": { "status": "not reported" }, "gross_margin": { "status": "not reported" }, "operating_margin": { "status": "not available" }, "pretax_income": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-05", "value_musd": -59.4 }, "net_income": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-05", "four_quarters_end": "2026-09-30", "value_musd": -59.5, "four_quarters_musd": -243.1 }, "operating_cash_flow": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-05", "first_end": "2025-12-31", "value_musd": -189.9 }, "capital_spending": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-05", "first_end": "2025-12-31", "value_musd": 0 }, "free_cash_flow": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-05", "first_end": "2025-12-31", "value_musd": -190 }, "diluted_share_change": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-05", "base_end": "2025-09-30", "pct": 10.6 }, "cash": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-05", "value_musd": 682.8 }, "debt": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-05", "value_musd": 59.7, "composition": "long-term debt" }, "net_cash": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-05", "value_musd": 623.1 }, "deferred_revenue": { "status": "not reported" }, "backlog": { "status": "not reported" }, "receivables": { "status": "not reported" }, "inventory": { "status": "not reported" }, "equity": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-05", "value_musd": 604.2 }, "market_value": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-29", "basis_filed": "2026-11-05", "value_musd": 3643.3 }, "enterprise_value": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-29", "basis_filed": "2026-11-05", "value_musd": 3020.2 }, "ev_sales": { "status": "not available" }, "ev_ebit": { "status": "not meaningful" }, "pe": { "status": "not meaningful" }, "pb": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-29", "basis_filed": "2026-11-05", "multiple": 6 }, "fcf_yield": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-29", "basis_filed": "2026-11-05", "pct": -5.2 } } }, "short_interest": { "status": "ok", "settlement": "2026-10-15", "published": "2026-10-26", "short_pct_of_outstanding": 16.38, "days_to_cover": 10.6, "change_pct": 2.6 }, "insiders": { "status": "ok", "as_of": "2026-11-15", "windows": [ { "days": 90, "status": "ok", "from": "2026-08-18", "bought_usd": 0, "sold_usd": 11877095.64, "bought_unpriced": 0, "sold_unpriced": 0 }, { "days": 365, "status": "ok", "from": "2025-11-16", "bought_usd": 0, "sold_usd": 48818714.15, "bought_unpriced": 0, "sold_unpriced": 0 } ] } }, "body_markdown": "## Current Thesis\n\nDisc Medicine's shares are modestly more likely than not to beat the S&P 500 over the next three months. Its lead drug, bitopertin, met every endpoint of the Phase 3 APOLLO trial on 2026-10-19, and that result answers the reason the Food and Drug Administration (FDA) rejected the drug in February. Two dated events settle it: pipeline data at the American Society of Hematology (ASH) meeting from 2026-12-12, and the new drug application (NDA) resubmission the company guides for the end of 2026.\n\nThe FDA issued a complete response letter (CRL) on 2026-02-13. HCPLive and PharmExec reported that the agency accepted that bitopertin lowers protoporphyrin IX (PPIX), the toxic metabolite behind erythropoietic protoporphyria (EPP), a rare disease that makes sunlight painful. It did not accept that the drop predicts clinical benefit, and it asked for data from another trial. In 183 patients, APOLLO cut PPIX by 41.4% against placebo (p<0.0001) and added 12.2 hours a month of time in light without pain (p=0.0010), according to the company's 2026-10-19 release. The company now seeks traditional approval, where the first filing sought accelerated approval, BioSpace reported on 2026-10-19.\n\nThe shares closed at $80.00 on 2026-11-13, down from $87.08 on 2026-11-11. The two lower closes spanned the company's fireside chat at the Stifel healthcare conference on 2026-11-12. The 3-month change is −0.1%: the shares stand where they stood in mid-August, after a slide to the 52-week closing low of $55.74 on 2026-10-14 and the recovery on the trial result.\n\nThe rating is Medium because the February letter's main question now has a direct answer and the company guides its cash to last into 2030. Against that, the company keeps issuing stock, insiders keep selling, and the FDA decision, guided for mid-2027, falls after the three-month window. The last close sits just above the kill line, so the coming sessions test the call directly.\n\n## Bull Case\n\n- **APOLLO answers the FDA's stated objection.** The CRL asked for proof that the PPIX drop means real benefit for patients. APOLLO showed a 12.2-hour monthly gain in pain-free time in light against placebo and met every secondary endpoint (company release, 2026-10-19).\n- **Funding runs into 2030.** Cash, equivalents and marketable securities were $682.8 million on 2026-09-30, before the October offering. The company says that cash plus the offering's proceeds funds operations into 2030 (third-quarter report, 2026-11-05).\n- **Management is planning the launch.** On 2026-11-09 Chief Executive Officer John Quisel said bitopertin could reach the market in 12 to 16 months. He cited about $1.1 billion of pro forma cash, an expected EPP price of about $300,000 a year and a planned 24-person sales force (Investing.com, 2026-11-10).\n- **Two more programs report at ASH.** On 2026-11-04 the company said it would present updated selcodebart data in anemia of myelofibrosis and DISC-3405 data at ASH. Quisel said on 2026-11-09 that the selcodebart Phase 3 design will be shared there, with a pivotal trial expected to start in 2027.\n- **Analyst targets moved up after the report.** Guggenheim started coverage with a Buy rating and a $132 target on 2026-11-09. HC Wainwright raised its target to $127 on 2026-11-06.\n\n## Bear Case\n\n- **New shares keep coming to market.** The company priced 6,000,000 shares at $75.00 on 2026-10-21, raising $450 million gross. On 2026-11-05 it filed an at-the-market sales agreement with TD Cowen for up to $189.93 million more, and the diluted share count was up 10.6% from a year earlier in the quarter to 2026-09-30.\n- **Insiders sell into strength.** Chief Medical Officer William Jacob Savage sold 16,035 shares at $85.09 on 2026-11-10 under a Rule 10b5-1 plan (Form 4 filed 2026-11-12). Director Kevin Bitterman sold 41,825 shares at an average of $80.13 from 2026-10-19 to 2026-10-21, and Quisel sold 33,000 shares at an average of $79.15 on 2026-08-17 after an option exercise (SEC Form 4 filings).\n- **Tolerability could shape the label.** Dizziness was the most common adverse event in APOLLO, reported in 50% of bitopertin patients and mostly mild or moderate, according to the company's 2026-11-05 update.\n- **The approval is still months away.** The company guides to an FDA decision by mid-2027. Until then, any gain in the shares has to come from filing milestones and pipeline data.\n- **The company burns cash.** Operating cash flow was −$190 million over the four quarters to 2026-09-30, and net loss was $243 million over the same period (Form 10-Q, filed 2026-11-05).\n\n## Setup & Price Structure\n\nThe shares closed at $80.00 on 2026-11-13, after $83.23 on 2026-11-12 and $87.08 on 2026-11-11. As of 2026-11-13, the 50-day moving average is $71.59 and the 200-day moving average is $70.95; the last close is above both.\n\nThe 52-week closing low is $55.74, set on 2026-10-14, five sessions before the APOLLO result. The 52-week intraday high is $99.50, set on 2025-12-08, before the rejection; the last close is 19.6% below it. A move back toward that high would mean the market treats the resubmission as close to a full reversal of the February letter.\n\nThe October offering priced at $75.00, and a common market view is that a large offering's price acts as a floor for the shares. Across liquid US stocks, the standard deviation of 63-session returns was 27% in 2026, so a three-month window for a single biotech carries wide swings in either direction.\n\n## Catalyst Calendar\n\n- **2026-12-12:** 68th ASH Annual Meeting (2026-12-12 to 2026-12-15): selcodebart myelofibrosis-anemia update and Phase 3 design, DISC-3405 polycythemia vera data. Shows whether the pipeline behind bitopertin holds up and when a second registration trial starts, which matters for value beyond a single EPP approval.\n- **~2026-12-31 (est.):** Bitopertin NDA resubmission to the FDA, guided for the end of 2026. Filing on time keeps the mid-2027 decision on track; the FDA's acknowledgment and goal date then set the review clock.\n- **~2026-12-31 (est.):** Selcodebart End-of-Phase 2 FDA feedback and pivotal plan for anemia of myelofibrosis. Sets whether a second program moves into a registration trial in 2027.\n- **~2027-06-30 (est.):** Expected FDA decision on the resubmitted bitopertin NDA (mid-2027 per company). Approval would make Disc Medicine a commercial company; a second rejection would remove most of the case.\n\n## What Would Change Our Mind\n\nA daily close below $78.47, the 2026-11-05 close on the day of the third-quarter report and the at-the-market filing, which would erase the post-report gains; or no bitopertin NDA resubmission announced by 2026-12-31.\n\nThe risks this note tracks, each with what would confirm it:\n\n- The bitopertin resubmission slips past the guided end-2026 timing. Confirmed by: No company announcement of the NDA resubmission by 2026-12-31.\n- The FDA sets a review goal later than mid-2027 or raises new questions on the resubmitted application. Confirmed by: A company disclosure of an FDA action date after 2027-06-30 or of an advisory committee meeting.\n- Share sales under the TD Cowen at-the-market program dilute holders and cap rallies. Confirmed by: At-the-market proceeds or a higher share count reported in the 2026 10-K.\n- Dizziness, reported in 50% of APOLLO bitopertin patients, leads to a restrictive label or weak uptake. Confirmed by: FDA labeling discussions or full APOLLO data showing discontinuations tied to dizziness.\n- Pipeline data at ASH disappoint and the market reprices the non-bitopertin programs. Confirmed by: Updated selcodebart or DISC-3405 data at ASH from 2026-12-12 showing weaker responses than earlier cohorts.\n\n## Correlation Notes\n\nDisc Medicine's shares trade mainly on the company's own regulatory and trial dates. The 2026-02-13 rejection and the 2026-10-19 APOLLO result drove the largest moves of the past year, and the 2026-10-21 offering set the price at which new institutional holders bought.\n\nOther rare-disease names in the same group, Viridian Therapeutics (VRDN), Xeris Biopharma (XERS), PepGen (PEPG), Liquidia (LQDA) and Eton Pharmaceuticals (ETON), depend on unrelated drugs, so their results say little about bitopertin's review. Headlines tagged with the IRON ticker about Ironveld plc, a UK-listed miner, appeared on 2026-10-30 and 2026-11-05; they concern a different company.", "first_seen": "2026-11-11", "last_analyzed": "2026-11-15T12:14:36+00:00", "last_synthesized": "2026-11-15", "date_modified": "2026-11-15", "license": "Content © FrontierPicks. Cite the canonical URL." }